Skip to main content
. Author manuscript; available in PMC: 2017 Jan 10.
Published in final edited form as: Mayo Clin Proc. 2016 Jan;91(1):101–119. doi: 10.1016/j.mayocp.2015.11.007

Table 5.

Revised International Staging System for Myeloma

Stage Frequency (% of patients) 5-year survival rate (%)
Stage 1

  • ISS Stage I (Serum albumin >3.5, Serum beta-2-microglobulin <3.5) and

  • No high risk cytogenetics

  • Normal LDH

 28% 82
Stage II

  • Neither Stage I or III

 62% 62
Stage III

  • ISS Stage III (Serum beta-2-microglobulin >5.5) and

  • High risk cytogenetics [t(4;14), t(14;16), or del(17p)] or Elevated LDH

 10% 40

From J Clin Oncol.37